WHAT YOU NEED TO KNOW MUST READ: CAPA Warns Recent Federal Circuit Court Decision Could Erode Hatch-Waxman, Lead to Even Higher Drug Prices Matthew Lane, executive director of the Coalition Against Patent Abuse (CAPA), recently authored an op-ed in Bloomberg Law around the Federal Circuit’s recent decision in GlaxoSmithKline LLCTeva Pharmaceuticals USA, Inc.: “The Federal Circuit’s decision in GlaxoSmithKline […]

Continue Reading

IN CASE YOU MISSED IT: Today, Bloomberg Law published an op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse (CAPA), around the Federal Circuit’s recent decision in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc. which undermines the ‘skinny label’ framework used by generic drug companies to describe their products as therapeutically equivalent to branded drugs.   In his op-ed, […]

Continue Reading

In case you missed it, please see the piece below in today’s Washington Post by two leading experts from Brigham and Women’s Hospital/Harvard Medical School that outlines how a Biden White House could take immediate steps address rising drug prices for patients and families by fixing our patent system….. Biden can lower drug prices without […]

Continue Reading